Biogen Pharmachem Industries Ltd (BIOGEN) is currently trading at 0.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Biogen Pharmachem Industries Limited is an India‑listed company primarily engaged in trading of shares, securities and commodities including agro products and precious metals, and has since 2021 changed its main objects to include pharmaceutical activities, although no material manufacturing or pharma operations are yet reported in the financial statements. The company reported mixed operating results for the period, with a quarterly loss of Rs. 49.15 lakhs but a positive six‑month profit before tax of Rs. 85.33 lakhs; earnings per share remain near zero and the statement shows limited operating revenue and other income volatility across periods. Balance sheet shows total assets of Rs. 9,917.53 lakhs as of September 30, 2025, dominated by non‑current financial assets comprising investments of Rs. 2,137.10 lakhs and long‑term loans of Rs. 7,549.39 lakhs, indicating an asset base concentrated in financial receivables and investments rather than operating plant or inventory. Liquidity and cash flows are constrained: operating cash flow for the half year was negative Rs. 44.78 lakhs, investing cash outflow was Rs. 750.35 lakhs principally due to investments and loans movement, while financing inflows included a preferential warrants receipt of Rs. 630.00 lakhs, resulting in a net cash decrease and low cash balances at period end. Corporate actions during the period include an increase in paid‑up share capital to Rs. 9,026.03 lakhs from Rs. 6,526.03 lakhs and a disclosed receipt from preferential allotment of Rs. 630.00 lakhs in cash flow, which materially changes the equity base and provides financial firepower for strategic activity or balance sheet realignment.

Over the past 52 weeks, Biogen Pharmachem Industries Ltd has traded between a low of ₹0.23 and a high of ₹0.72. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Biogen Pharmachem Industries Ltd has a market capitalization of approximately 26.33. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Biogen Pharmachem Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -154.88 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 26.33 Cr, Biogen Pharmachem Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Biogen Pharmachem Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Biogen Pharmachem Industries Ltd is -154.88. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It is a strategic initiative with a ₹10,000 crore outlay over five years to develop India as a global biopharma manufacturing hub, focusing on biologics, research, and building a supportive ecosystem.